If you’re in crisis or having thoughts of suicide, help is available 24/7. Call or text 988 to reach the Suicide & Crisis Lifeline, call 911 for any life-threatening emergency, or call 833-773-2445 for the Massachusetts Behavioral Health Help Line.
If you’ve tried two or more antidepressants and still feel the weight of depression every morning, you are not alone, and you have not run out of options. Treatment-resistant depression affects a meaningful share of people who seek care, and for years the standard answer was simply to try another pill and wait. That is changing. At Cambridge Biotherapies™, our team offers Boston patients access to advanced, evidence-based therapies that work differently from traditional antidepressants and often work faster. This post walks through what treatment-resistant depression means, why it happens, and the treatment paths most relevant to patients searching for treatment resistant depression Boston care: ketamine infusion therapy, SPRAVATO® (esketamine), TMS, and integrated psychiatric support. You will learn how each option works, who it’s best suited for, and what to expect when you walk into our treatment center.
What Treatment-Resistant Depression Actually Means
The term sounds clinical, but the experience is deeply personal. You’ve followed your doctor’s plan. You’ve taken the medication for weeks, maybe months. And the depression is still there.
Clinically, treatment-resistant depression (often shortened to TRD) refers to major depressive disorder that has not responded adequately to at least two trials of antidepressant medications at appropriate doses and durations. According to research published in the Journal of Clinical Psychiatry, approximately 2.8 million U.S. adults, or 30.9% of those treated for major depression, have treatment-resistant depression. And data from the landmark STAR*D trial showed that roughly one in three patients achieves remission on a first antidepressant, with remission becoming progressively less likely after each subsequent medication step.
Those numbers matter because they tell you something important: if antidepressants alone haven’t worked for you, that outcome is common, it is not your fault, and there are other validated tools available.
Why Some Depression Doesn’t Respond to Antidepressants
Traditional antidepressants like SSRIs and SNRIs work primarily by adjusting serotonin or norepinephrine levels in the brain over a span of four to six weeks. For many people, that approach helps. For others, it doesn’t, and researchers now believe the reasons go beyond a single neurotransmitter.
Depression is increasingly understood as a condition that involves several brain systems at once, including glutamate signaling, neural circuit activity, inflammation, and the brain’s capacity for synaptic plasticity (the ability of neurons to form new connections). When the dysfunction sits in those other systems, an SSRI may simply not be the right tool. Risk factors that often accompany treatment-resistant patterns include:
- Earlier onset of depression, often in adolescence or early adulthood
- A history of trauma or chronic stress
- Co-occurring anxiety, PTSD, or OCD
- Chronic medical conditions, including thyroid disorders or chronic pain
- A family history of mood disorders
- Long depressive episodes before starting treatment
Understanding the biology helps explain why the next step often isn’t “another pill in the same class.” It’s a different mechanism entirely. For a fuller picture of how we evaluate and treat the underlying condition, our depression treatment page goes into more detail.
Ketamine Infusion Therapy: Rapid Relief Through a Different Pathway
IV ketamine therapy works through the glutamate system rather than serotonin, and that mechanism is the reason it can act so quickly. According to Harvard Health Publishing, ketamine produces rapid antidepressant effects within hours to days, compared to weeks for traditional antidepressants.
The evidence base has grown substantially in recent years. In a 2023 Mass General Brigham clinical trial of 403 patients with treatment-resistant depression, 55% of those who received ketamine experienced sustained improvement in depressive symptoms without major side effects. For people who have spent years cycling through medications without meaningful improvement, that pace of change can feel almost disorienting at first.
At our Cambridge treatment center, IV ketamine is administered in a quiet, medically supervised setting by licensed clinicians. A typical course involves a series of infusions over several weeks, with each session monitored from start to finish. Most patients describe the experience itself as introspective and dreamlike, and they go home the same day with a trusted person to accompany them.
It’s worth being clear about the regulatory picture. Ketamine is FDA-approved as an anesthetic and is a Schedule III controlled substance. Its use for depression, anxiety, PTSD, OCD, and other psychiatric conditions is considered off-label.
SPRAVATO® (Esketamine): The FDA-Approved Path
If you’d prefer a treatment that carries direct FDA approval for treatment-resistant depression, SPRAVATO® therapy is the option to consider. SPRAVATO® is a nasal spray version of esketamine, a molecule closely related to ketamine, and it is administered under direct healthcare provider supervision in a certified setting like ours.
SPRAVATO® is FDA-approved for adults with treatment-resistant depression, used in conjunction with an oral antidepressant. In the TRD4005 trial, 22.5% of patients treated with SPRAVATO® achieved remission at week 4, compared to 7.6% on placebo
Here is what makes SPRAVATO® stand out for many Boston patients we see:
- It carries FDA approval specifically for TRD, which often translates to insurance coverage
- It’s administered in our REMS-certified outpatient setting with monitoring for at least two hours after each dose
- It pairs well with ongoing therapy and oral antidepressants
- Sessions take place onsite, with no needles and no IV
SPRAVATO® carries Boxed Warnings for sedation, dissociation, abuse and misuse, and suicidal thoughts and behaviors. It is available only through the SPRAVATO® REMS program and must never be dispensed for home use. Cambridge Biotherapies is a SPRAVATO® REMS-certified outpatient healthcare setting, so the full treatment, from dosing to recovery monitoring, happens under one roof.
TMS Therapy: Non-Invasive, Drug-Free, and Backed by Strong Evidence
Transcranial Magnetic Stimulation (TMS) takes an entirely different approach. Instead of working through the bloodstream, TMS uses targeted magnetic pulses to stimulate the regions of the brain involved in mood regulation, particularly the left dorsolateral prefrontal cortex. You sit comfortably in a chair, awake and alert, while a coil delivers pulses to a precise spot on your scalp. Sessions last around 20 to 40 minutes, and there’s no anesthesia, no medication, and no recovery time. Most patients drive themselves home and return to work the same day.
TMS is FDA-cleared as a non-invasive medical device (not FDA-approved as a drug) for the treatment of major depressive disorder (since 2008), obsessive-compulsive disorder (adjunct, since 2018), anxious depression (since 2021), and adolescent depression ages 15 to 21 (adjunct, cleared March 2024), in patients who have not achieved satisfactory improvement from prior antidepressant medication.
The evidence is strong. A meta-analysis of 19 randomized sham-controlled trials found that rTMS as add-on therapy after two antidepressant failures showed a risk ratio of 2.25 for response and 2.78 for remission compared to standard pharmacotherapy. For patients who want to avoid medications or who have not tolerated them well, TMS is often the most natural next step.
We also offer Accelerated TMS protocols, which condense treatment into a shorter timeframe for patients whose schedules or symptom severity call for a faster course.
How to Choose Among These Options
There isn’t a single best path. The right choice depends on your medical history, what you’ve already tried, your insurance coverage, your schedule, and your personal preferences about how a treatment feels.
Here’s a rough framing many of our Boston patients find useful:
- If you want rapid relief and are open to off-label care, ketamine often acts within days
- If you want an FDA-approved option for TRD with strong insurance coverage, SPRAVATO® is usually the first conversation
- If you want a drug-free, non-invasive option with one of the strongest evidence bases for depression, TMS deserves serious consideration
- If you’re not sure, that’s exactly what our consultation is for
According to the National Institute of Mental Health (NIMH), depression treatment often involves combining approaches, and decisions are best made in partnership with a psychiatric specialist who knows your full history.
Why Boston Patients Choose Cambridge Biotherapies
Our founder and Chief Medical Officer, Dr. Daniel A. Brenner, is a board-certified psychiatrist who trained at Harvard Medical School and served as Chief Resident at Cambridge Hospital. Our clinical team includes psychiatric nurse practitioners formerly with Massachusetts General Hospital, a social worker with more than 20 years of experience, and licensed clinicians who specialize specifically in interventional psychiatry.
We are LegitScript-certified, SPRAVATO® REMS-certified, and members of the American Society of Ketamine Physicians. Most major Massachusetts insurers, including Blue Cross Blue Shield MA, Harvard Pilgrim, Mass General Brigham Health Plan, Aetna, Cigna, Optum, and Tricare, are accepted for the treatments where coverage applies. You can review the full list on our insurance coverage page.
Geographically, Our treatment center at 6 Bigelow Street sits just off Central Square in Cambridge, a few minutes’ walk from the Central Square Red Line stop and easily reachable from Boston, about 25 minutes from Back Bay. Patients coming from Beacon Hill can hop one stop to Charles/MGH and connect across, and those in the South End or Fenway typically reach us in under 25 minutes via public transit.
Taking the Next Step
Treatment-resistant depression can make the future feel small. But the landscape of care has changed significantly in the last decade, and the four pathways above represent some of the most promising progress in modern psychiatry. If you are searching for relief that hasn’t come from medication alone, we’d be honored to help you understand which option fits your situation best.
Take The First Step Now. Reach out to our care team for a confidential consultation, and we’ll walk you through the evaluation process, insurance questions, and what your first visit looks like.
Medically reviewed by Daniel A. Brenner, M.D. Board-Certified Psychiatrist, Founder & Chief Medical Officer, Cambridge Biotherapies™ Harvard University (BA) • Tufts University School of Medicine (MD) • Cambridge Hospital/Harvard Medical School Residency (Chief Resident) • Teaching Associate in Psychiatry, Harvard Medical School • 25+ years in private practice
Cambridge Biotherapies™ 6 Bigelow Street, Cambridge, MA 02139
Phone: (888) 646-0566
Emergency Information Our team is available during staffed hours only. If you are experiencing a mental health emergency, please seek help immediately:
- Call 911 for any life-threatening emergency
- Call or text 988 to reach the Suicide & Crisis Lifeline (24/7)
- Call 833-773-2445 to reach the Massachusetts Behavioral Health Help Line (24/7)
- Or contact your psychiatrist, therapist, or primary care provider
Disclaimer: The information on this page is for educational purposes only and is not medical advice. It is not a substitute for professional diagnosis or treatment. Always seek the guidance of your physician or qualified mental health provider with questions about a medical condition. Treatments described here are administered only after individual medical evaluation; outcomes vary by patient.
Ketamine is FDA-approved as an anesthetic and is a Schedule III controlled substance. Its use for depression, anxiety, PTSD, OCD, and other psychiatric conditions is considered off-label. Cambridge Biotherapies administers ketamine in a medically supervised clinical setting by licensed providers in accordance with applicable state and federal regulations. Compounded ketamine products dispensed for home use are not FDA-approved and have been the subject of FDA safety alerts. Individual treatment decisions are made following a clinical evaluation.
SPRAVATO® (esketamine) is a Schedule III controlled substance, FDA-approved for treatment-resistant depression and for depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior (the latter in conjunction with an oral antidepressant). SPRAVATO® carries Boxed Warnings for sedation, dissociation, abuse and misuse, and suicidal thoughts and behaviors. Because of these risks, SPRAVATO® is available only through a restricted distribution program called the SPRAVATO® REMS. It must be administered under the direct observation of a healthcare provider in a certified healthcare setting, with patients monitored for at least two hours after each dose. SPRAVATO® must never be dispensed for home use. Cambridge Biotherapies is a SPRAVATO® REMS-certified outpatient healthcare setting.
Transcranial Magnetic Stimulation (TMS) is FDA-cleared as a non-invasive medical device (not FDA-approved as a drug) for the treatment of major depressive disorder, obsessive-compulsive disorder (adjunct), anxious depression, and adolescent depression ages 15 to 21, among other indications, in patients who have not achieved satisfactory improvement from prior antidepressant medication. Coverage of specific indications varies by device manufacturer and insurer.